Lisanti Capital Growth LLC Acquires 14,485 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Lisanti Capital Growth LLC raised its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 24.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 72,600 shares of the biopharmaceutical company's stock after purchasing an additional 14,485 shares during the quarter. Intra-Cellular Therapies accounts for approximately 1.5% of Lisanti Capital Growth LLC's portfolio, making the stock its 16th largest position. Lisanti Capital Growth LLC owned about 0.07% of Intra-Cellular Therapies worth $6,064,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of ITCI. Wealth Enhancement Advisory Services LLC increased its position in shares of Intra-Cellular Therapies by 185.6% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 8,810 shares of the biopharmaceutical company's stock worth $645,000 after acquiring an additional 5,725 shares in the last quarter. US Bancorp DE boosted its stake in Intra-Cellular Therapies by 3.3% during the 3rd quarter. US Bancorp DE now owns 7,951 shares of the biopharmaceutical company's stock valued at $582,000 after purchasing an additional 251 shares during the last quarter. M&G PLC bought a new stake in Intra-Cellular Therapies during the 3rd quarter worth approximately $9,076,000. Principal Financial Group Inc. raised its stake in shares of Intra-Cellular Therapies by 3.3% in the third quarter. Principal Financial Group Inc. now owns 597,713 shares of the biopharmaceutical company's stock worth $43,735,000 after purchasing an additional 18,865 shares during the last quarter. Finally, Quantum Private Wealth LLC lifted its holdings in shares of Intra-Cellular Therapies by 1.0% in the third quarter. Quantum Private Wealth LLC now owns 38,661 shares of the biopharmaceutical company's stock valued at $2,829,000 after purchasing an additional 400 shares in the last quarter. Institutional investors and hedge funds own 92.33% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

Several brokerages recently issued reports on ITCI. Canaccord Genuity Group downgraded Intra-Cellular Therapies from a "buy" rating to a "hold" rating and upped their price target for the stock from $119.00 to $132.00 in a report on Friday, January 31st. Royal Bank of Canada reiterated a "sector perform" rating and issued a $132.00 target price (up previously from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd. StockNews.com started coverage on shares of Intra-Cellular Therapies in a report on Tuesday, March 4th. They set a "hold" rating on the stock. Mizuho lowered shares of Intra-Cellular Therapies from an "outperform" rating to a "neutral" rating and decreased their price objective for the company from $140.00 to $132.00 in a research note on Monday, February 24th. Finally, Needham & Company LLC restated a "hold" rating on shares of Intra-Cellular Therapies in a research note on Friday, February 21st. Ten research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $106.08.

Intra-Cellular Therapies Trading Down 0.0 %

Shares of ITCI stock traded down $0.01 during trading on Tuesday, reaching $131.24. 3,206,388 shares of the company's stock traded hands, compared to its average volume of 1,307,650. Intra-Cellular Therapies, Inc. has a 1 year low of $63.30 and a 1 year high of $131.37. The company has a market capitalization of $13.95 billion, a P/E ratio of -150.85 and a beta of 0.69. The firm's 50-day moving average is $120.15 and its 200 day moving average is $94.08.

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last posted its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.08). The company had revenue of $199.22 million during the quarter, compared to the consensus estimate of $205.08 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. As a group, sell-side analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.